Abstract
Chikungunya virus (CHIKV) infection is a re-emerging arboviral disease in tropical and subtropical regions. In addition to acute febrile syndrome, CHIKV infection may lead to chronic articular manifestations that significantly affect a long-term quality of life. This study aimed to design a universal vaccine candidate covering all circulating genotypes of CHIKV based on conserved multiepitope platform. We employed a large scale phylogenetic and immunoinformatic approach to identify conserved regions of the open reading frames (ORF2) region encoding viral structural proteins. This study ultimately identified 10 high-quality epitopes: 6 MHC-I, 1 MHC-II, and 3 B cell epitopes. The selected epitopes span multiple viral domains, including C, E1, E2, and E3, with high immunogenicity (VaxiJen ≥ 66%), non-toxic, and non-allergenic properties. These selected epitopes were utilized to design multiepitope vaccine constructs (MEV-CHIKV) linked with various linkers in combination with adjuvants (human β-defensin 3) to enhance the immune responses. Structural validation analysis showed high quality and stability of the vaccine construct. Based on molecular docking analysis, the designed vaccine has high binding affinities with the active site of TLR3. In silico immune simulation showed induction of robust adaptive immune responses, characterized by the activation and expansion of B and T cell populations. Codon optimization and rare codon analysis revealed a potentially high expression in bacterial system. Thus, the vaccine cadidate is anticipated to effectively and simultaneously induce robust cellular and humoral immune responses. In addition, it should retain its high protection upon emergence of novel mutations within the CHIKV genome. Since our study is merely in silico-based analysis, further in vitro and in vivo experimental validation to demonstrate the immunogenic properties of the vaccine candidate are still needed.
Similar content being viewed by others
Data availability
All data generated or analyzed during this study are included in this published article and its supplementary information files. Further inquiries can be directed to the corresponding author.
References
Hakim, M. S. & Aman, A. T. Understanding the biology and immune pathogenesis of chikungunya virus infection for diagnostic and vaccine development. Viruses 15, 48. https://doi.org/10.3390/v15010048 (2023).
Silva, M. M. O. et al. Concomitant transmission of dengue, chikungunya, and Zika viruses in Brazil: Clinical and epidemiological findings from surveillance for acute febrile illness. Clin. Infect. Dis. 69, 1353–1359. https://doi.org/10.1093/cid/ciy1083 (2019).
Vidal, E. R. N., Frutuoso, L. C. V., Duarte, E. C. & Peixoto, H. M. Epidemiological burden of chikungunya fever in Brazil, 2016 and 2017. Trop. Med. Int. Health. 27, 174–184. https://doi.org/10.1111/tmi.13711 (2022).
Mavalankar, D., Shastri, P., Bandyopadhyay, T., Parmar, J. & Ramani, K. V. Increased mortality rate associated with chikungunya epidemic, Ahmedabad, India. Emerg. Infect. Dis. 14, 412–415. https://doi.org/10.3201/eid1403.070720 (2008).
Simiao, A. R. et al. A major Chikungunya epidemic with high mortality in Northeastern Brazil. Rev. Soc. Bras. Med. Trop. 52, e20190266. https://doi.org/10.1590/0037-8682-0266-2019 (2019).
Costa, L. B. et al. Epidemiology and economic burden of chikungunya: A systematic literature review. Trop. Med. Infect. Dis. 8, 301. https://doi.org/10.3390/tropicalmed8060301 (2023).
Lum, F. M. et al. An essential role of antibodies in the control of chikungunya virus infection. J. Immunol. 190, 6295–6302. https://doi.org/10.4049/jimmunol.1300304 (2013).
Henss, L. et al. Analysis of humoral immune responses in chikungunya virus (CHIKV)-infected patients and individuals vaccinated with a candidate CHIKV vaccine. J. Infect. Dis. 221, 1713–1723. https://doi.org/10.1093/infdis/jiz658 (2020).
Kam, Y. W. et al. Early neutralizing IgG response to chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein. EMBO Mol. Med. 4, 330–343. https://doi.org/10.1002/emmm.201200213 (2012).
Tumkosit, U. et al. Anti-chikungunya virus monoclonal antibody that inhibits viral fusion and release. J. Virol. 94, e00252–e00220. https://doi.org/10.1128/JVI.00252-20 (2020).
Hoarau, J. J. et al. Identical strength of the T cell responses against E2, nsP1 and capsid CHIKV proteins in recovered and chronic patients after the epidemics of 2005–2006 in La reunion Island. PLoS One. 8, e84695. https://doi.org/10.1371/journal.pone.0084695 (2013).
Weber, W. C., Streblow, D. N. & Coffey, L. L. Chikungunya virus vaccines: A review of IXCHIQ and PXVX0317 from pre-clinical evaluation to licensure. BioDrugs. 38, 727–742. https://doi.org/10.1007/s40259-024-00677-y (2024).
Schneider, M. et al. Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: A double-blind, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 401, 2138–2147. https://doi.org/10.1016/S0140-6736(23)00641-4 (2023).
CDC. Chikungunya Vaccines, accessed 18 July; Available from: https://www.cdc.gov/chikungunya/vaccines/index.html (2025).
Akbari, E., Seyedinkhorasani, M. & Bolhassani, A. Conserved multiepitope vaccine constructs: A potent HIV-1 therapeutic vaccine in clinical trials. Braz J. Infect. Dis. 27, 102774. https://doi.org/10.1016/j.bjid.2023.102774 (2023).
Zhang, L. Multi-epitope vaccines: A promising strategy against tumors and viral infections. Cell. Mol. Immunol. 15, 182–184. https://doi.org/10.1038/cmi.2017.92 (2018).
Pandey, A., Madan, R. & Singh, S. Immunology to immunotherapeutics of SARS-CoV-2: Identification of immunogenic epitopes for vaccine development. Curr. Microbiol. 79, 306. https://doi.org/10.1007/s00284-022-03003-3 (2022).
Sanami, S. et al. In silico design of a multi-epitope vaccine against HPV16/18. BMC Bioinform. 23, 311. https://doi.org/10.1186/s12859-022-04784-x (2022).
Aiman, S. et al. Multi-epitope chimeric vaccine design against emerging Monkeypox virus via reverse vaccinology techniques—a bioinformatics and immunoinformatics approach. Front. Immunol. 13, 985450. https://doi.org/10.3389/fimmu.2022.985450 (2022).
Chathuranga, W. A. G. et al. Efficacy of a novel multiepitope vaccine candidate against foot-and-mouth disease virus serotype O and A. Vaccines (Basel). 10, 2181. https://doi.org/10.3390/vaccines10122181 (2022).
Qi, W. et al. A novel multi-epitope vaccine of HPV16 E5E6E7 oncoprotein delivered by HBc VLPs induced efficient prophylactic and therapeutic antitumor immunity in tumor mice model. Vaccine 40, 7693–7702. https://doi.org/10.1016/j.vaccine.2022.10.069 (2022).
Adu-Bobie, J., Capecchi, B., Serruto, D., Rappuoli, R. & Pizza, M. Two years into reverse vaccinology. Vaccine 21, 605–610. https://doi.org/10.1016/s0264-410x(02)00566-2 (2003).
Hakim, M. S., Annisa, L., Gazali, F. M. & Aman, A. T. The origin and continuing adaptive evolution of chikungunya virus. Arch. Virol. 167, 2443–2455. https://doi.org/10.1007/s00705-022-05570-z (2022).
Salvatierra, K. & Florez, H. Pathogen sequence signature analysis (PSSA): A software tool for analyzing sequences to identify microorganism genotypes [version 1; peer review: 2 approved with reservations]. F1000Research 6(21). https://doi.org/10.12688/f1000research.10393.1 (2017).
Shen, W., Le, S., Li, Y., Hu, F. & SeqKit A cross-platform and ultrafast toolkit for FASTA/Q file manipulation. PLoS One. 11, e0163962. https://doi.org/10.1371/journal.pone.0163962 (2016).
Danecek, P. et al. Twelve years of samtools and BCFtools. Gigascience 10, giab008. https://doi.org/10.1093/gigascience/giab008 (2021).
Li, H. et al. The sequence alignment/map format and samtools. Bioinformatics 25, 2078–2079. https://doi.org/10.1093/bioinformatics/btp352 (2009).
Katoh, K. & Standley, D. M. MAFFT multiple sequence alignment software version 7: Improvements in performance and usability. Mol. Biol. Evol. 30, 772–780. https://doi.org/10.1093/molbev/mst010 (2013).
Darriba, D. et al. ModelTest-NG: A new and scalable tool for the selection of DNA and protein evolutionary models. Mol. Biol. Evol. 37, 291–294. https://doi.org/10.1093/molbev/msz189 (2020).
Edler, D., Klein, J., Antonelli, A. & Silvestro, D. RaxmlGUI 2.0: A graphical interface and toolkit for phylogenetic analyses using RAxML. Methods Ecol. Evol. 12, 373–377 (2021).
Fu, L., Niu, B., Zhu, Z., Wu, S. & Li, W. CD-HIT: Accelerated for clustering the next-generation sequencing data. Bioinformatics 28, 3150–3152. https://doi.org/10.1093/bioinformatics/bts565 (2012).
Edgar, R. C. MUSCLE v5 Enables Improved Estimates of Phylogenetic Tree Confidence by Ensemble Bootstrapping. bioRxiv, 2021.2006.2020.449169. https://doi.org/10.1101/2021.06.20.449169 (2021).
Rice, P., Longden, I. & Bleasby, A. EMBOSS: The European molecular biology open software suite. Trends Genet. 16, 276–277. https://doi.org/10.1016/s0168-9525(00)02024-2 (2000).
Reynisson, B., Alvarez, B., Paul, S., Peters, B. & Nielsen, M. NetMHCpan-4.1 and NetMHCIIpan-4.0: Improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 48, W449–W454. https://doi.org/10.1093/nar/gkaa379 (2020).
Jespersen, M. C., Peters, B., Nielsen, M. & Marcatili, P. BepiPred-2.0: Improving sequence-based B-cell epitope prediction using conformational epitopes. Nucleic Acids Res. 45, W24–W29. https://doi.org/10.1093/nar/gkx346 (2017).
Doytchinova, I. A., Flower, D. R. & VaxiJen A server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinform. 8, 4. https://doi.org/10.1186/1471-2105-8-4 (2007).
Dimitrov, I., Bangov, I., Flower, D. R. & Doytchinova, I. AllerTOP v.2–a server for in silico prediction of allergens. J. Mol. Model. 20, 2278. https://doi.org/10.1007/s00894-014-2278-5 (2014).
Rathore, A. S., Choudhury, S., Arora, A., Tijare, P. & Raghava, G. P. ToxinPred 3.0: An improved method for predicting the toxicity of peptides. Comput. Biol. Med. 179, 108926. https://doi.org/10.1016/j.compbiomed.2024.108926 (2024).
Naderian, R. et al. Rational design of multi-epitope vaccine for Chandipura virus using an immunoinformatics approach. PLoS One. 20, e0335147. https://doi.org/10.1371/journal.pone.0335147 (2025).
McGuffin, L. J., Bryson, K. & Jones, D. T. The PSIPRED protein structure prediction server. Bioinformatics 16, 404–405. https://doi.org/10.1093/bioinformatics/16.4.404 (2000).
Zheng, W. et al. Deep-learning-based single-domain and multidomain protein structure prediction with D-I-TASSER. Nat. Biotechnol. https://doi.org/10.1038/s41587-025-02654-4 (2025).
Heo, L., Park, H., Seok, C. & GalaxyRefine Protein structure refinement driven by side-chain repacking. Nucleic Acids Res. 41, W384–388. https://doi.org/10.1093/nar/gkt458 (2013).
Wiederstein, M. & Sippl, M. J. ProSA-web: Interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res. 35, W407–410. https://doi.org/10.1093/nar/gkm290 (2007).
Williams, C. J. et al. More and better reference data for improved all-atom structure validation. Protein Sci. 27, 293–315. https://doi.org/10.1002/pro.3330 (2018). MolProbity.
Jimenez-Garcia, B., Teixeira, J. M. C., Trellet, M., Rodrigues, J. & Bonvin, A. PDB-tools web: A user-friendly interface for the manipulation of PDB files. Proteins 89, 330–335. https://doi.org/10.1002/prot.26018 (2021).
Aghahosseini, F., Bayat, M., Sadeghian, Z., Gheidari, D. & Safari, F. Synthesis, molecular docking study, MD simulation, ADMET, and drug likeness of new thiazolo[3,2-a]pyridine-6,8-dicarbonitrile derivatives as potential anti-diabetic agents. PLoS One. 19, e0306973. https://doi.org/10.1371/journal.pone.0306973 (2024).
Ambrosetti, F., Jandova, Z. & Bonvin, A. Information-driven antibody-antigen modelling with HADDOCK. Methods Mol. Biol. 2552, 267–282. https://doi.org/10.1007/978-1-0716-2609-2_14 (2023).
Seeliger, D. & de Groot, B. L. Ligand Docking and binding site analysis with PyMOL and Autodock/Vina. J. Comput. Aided Mol. Des. 24, 417–422. https://doi.org/10.1007/s10822-010-9352-6 (2010).
Rapin, N., Lund, O. & Castiglione, F. Immune system simulation online. Bioinformatics 27, 2013–2014. https://doi.org/10.1093/bioinformatics/btr335 (2011).
Grote, A. et al. JCat: A novel tool to adapt codon usage of a target gene to its potential expression host. Nucleic Acids Res. 33, W526–531. https://doi.org/10.1093/nar/gki376 (2005).
CDC. Chikungunya Virus Disease Worldwide Overview, accessed 20 July; Available from: https://www.ecdc.europa.eu/en/chikungunya-monthly (2025).
EMA. EMA Starts Review of Ixchiq (Live Attenuated Chikungunya Vaccine), accessed 20 July; Available from: https://www.ema.europa.eu/en/news/ema-starts-review-ixchiq-live-attenuated-chikungunya-vaccine (2025).
The US FDA. FDA Update on the Safety of Ixchiq (Chikungunya Vaccine, Live). FDA Suspends Biologics License: FDA Safety Communication., accessed 19 Jan; Available from: https://www.fda.gov/safety/medical-product-safety-information/fda-update-safety-ixchiq-chikungunya-vaccine-live-fda-suspends-biologics-license-fda-safety (2026).
Backert, L. & Kohlbacher, O. Immunoinformatics and epitope prediction in the age of genomic medicine. Genome Med. 7, 119. https://doi.org/10.1186/s13073-015-0245-0 (2015).
Tahir, U. et al. Peptide vaccine against chikungunya virus: Immuno-informatics combined with molecular docking approach. J. Transl Med. 16, 298. https://doi.org/10.1186/s12967-018-1672-7 (2018).
Narula, A., Pandey, R. K., Khatoon, N., Mishra, A. & Prajapati, V. K. Excavating chikungunya genome to design B and T cell multi-epitope subunit vaccine using comprehensive immunoinformatics approach to control Chikungunya infection. Infect. Genet. Evol. 61, 4–15. https://doi.org/10.1016/j.meegid.2018.03.007 (2018).
Sohail, M. S., Ahmed, S. F., Quadeer, A. A. & McKay, M. R. In Silico T cell epitope identification for SARS-CoV-2: Progress and perspectives. Adv. Drug Deliv Rev. 171, 29–47. https://doi.org/10.1016/j.addr.2021.01.007 (2021).
Lani, R. et al. From defense to offense: Modulating toll-like receptors to combat arbovirus infections. Hum. Vaccin Immunother. 20, 2306675. https://doi.org/10.1080/21645515.2024.2306675 (2024).
Garcia, G. Jr. et al. Innate immune pathway modulator screen identifies STING pathway activation as a strategy to inhibit multiple families of Arbo and respiratory viruses. Cell. Rep. Med. 4, 101024. https://doi.org/10.1016/j.xcrm.2023.101024 (2023).
Acknowledgements
The author would like to thank Aqsa Ikram (the University of Lahore, Pakistan) and Faris M. Gazali (Universitas Gadjah Mada, Indonesia) for their technical assistance during the early phase of this project. The author would like to thank the Deanship of Graduate Studies and Scientific Research at Qassim University for financial support (QU-APC-2026).
Funding
The authors declare that no funds or grants were received to support this work.
Author information
Authors and Affiliations
Contributions
M. S. H. was involved in conceptualization, data acquisition, data analysis, writing original draft, editing, and finalization.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Hakim, M.S. Reverse vaccinology-based design of a universal multiepitope vaccine against chikungunya virus: Phylogenetic and immunoinformatics approaches. Sci Rep (2026). https://doi.org/10.1038/s41598-026-39790-z
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-026-39790-z
